Etoricoxib
Reading File
Finding Sources
Searching PubMed
etoricoxib clinical pharmacology
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information to provide a detailed answer on etoricoxib. Let me compile it.
Etoricoxib
Drug Class & Mechanism
Etoricoxib is a selective COX-2 inhibitor (coxib class of NSAIDs). Among all coxibs, its COX-2 selectivity is second only to lumiracoxib. It works by selectively inhibiting cyclooxygenase-2 (COX-2), the inducible isoform upregulated by cytokines, shear stress, and tumor promoters at sites of inflammation.
- COX-2 is the dominant source of prostanoid formation in inflammation
- By sparing COX-1 (the constitutive, "housekeeping" isoform), etoricoxib preserves gastric mucosal cytoprotection and platelet TXA2 production - giving it a GI safety advantage over non-selective NSAIDs
- The structural basis for selectivity: coxibs have a bulky side group that fits a large side pocket in COX-2's arachidonic acid-binding channel but is sterically hindered in the smaller COX-1 channel
Pharmacokinetics (ADME)
| Parameter | Detail |
|---|---|
| Bioavailability | ~80% (incompletely absorbed) |
| Half-life (t½) | 20-26 hours |
| Dosing frequency | Once daily |
| Protein binding | Extensive |
| Metabolism | Extensive hepatic metabolism before excretion |
| Renal clearance | Renal insufficiency does NOT affect drug clearance |
| Hepatic impairment | Patients prone to drug accumulation - dose reduction required |
The long half-life (~22 hours) makes once-daily dosing effective, distinguishing it from shorter-acting NSAIDs.
Approved Indications & Dosing
| Indication | Dose |
|---|---|
| Osteoarthritis | 60 mg once daily |
| Rheumatoid arthritis | 90 mg once daily |
| Ankylosing spondylitis / Axial SpA | 90 mg once daily (max approved 90 mg) |
| Acute gouty arthritis | 120 mg once daily (short term) |
| Acute musculoskeletal pain | 60-90 mg once daily |
| Postoperative pain | 90-120 mg once daily |
| Primary dysmenorrhea | 120 mg once daily |
In ankylosing spondylitis, both etoricoxib 90 mg/day and 120 mg/day have been shown superior to naproxen 1000 mg/day, which itself was superior to placebo (Rheumatology, 2-Volume Set, 2022).
Therapeutic Uses
- Osteoarthritis - symptomatic relief of joint pain and stiffness
- Rheumatoid arthritis - anti-inflammatory and analgesic (does NOT modify disease course)
- Ankylosing spondylitis / Axial spondyloarthritis - one of the most effective NSAIDs studied in this indication
- Acute gouty arthritis - rapid pain relief during acute flares
- Musculoskeletal pain - short-term use
- Postoperative pain - acute setting
- Primary dysmenorrhea - menstrual pain
- Hypertrophic osteoarthropathy (HOA) - case reports show reversal of clubbing and pachydermia, attributed to its potent prostaglandin inhibition
Adverse Effects
Cardiovascular (most important)
- Increased risk of myocardial infarction and stroke - a class effect of COX-2 inhibitors
- Mechanism: COX-2-derived prostacyclin (PGI2) is an endogenous inhibitor of thrombosis and causes vasodilation; its inhibition shifts the balance toward TXA2-driven platelet aggregation and vasoconstriction
- Can cause or exacerbate hypertension and peripheral edema (via renal PG inhibition)
- Contraindicated in patients at high cardiovascular risk (in Europe; US: not approved at all)
GI Effects
- Better GI tolerability than non-selective NSAIDs (due to COX-1 sparing)
- However, the GI advantage is lost when co-administered with low-dose aspirin
- The MEDAL programme (Multinational Etoricoxib and Diclofenac Arthritis Long-term) showed etoricoxib was associated with fewer upper GI events than diclofenac
Renal Effects
- Fluid retention, hypertension (class effect - renal prostaglandins regulate sodium excretion and blood pressure)
Hepatic
- Drug accumulation in hepatic impairment (dose adjustment needed)
Drug Interactions & Precautions
- Co-administration with low-dose aspirin negates the GI benefit
- Patients on aspirin AND etoricoxib still have increased cardiovascular risk compared to aspirin alone
- For high cardiovascular risk patients on aspirin: any NSAID (including naproxen) increases CV risk further - a PPI + naproxen combination is preferred if GI protection is also needed
- Coxib + PPI is the regimen of choice for patients at high GI risk but lower CV risk
Regulatory Status
| Region | Status |
|---|---|
| United States | NOT approved (FDA has not approved etoricoxib) |
| Europe | Marketed in most countries (alongside celecoxib) |
| India | Available and widely used |
Etoricoxib and lumiracoxib were never approved by the FDA. In Europe, etoricoxib and diclofenac/celecoxib are contraindicated in patients at high cardiovascular risk (unlike in the US where celecoxib carries only a warning).
Comparison with Other Coxibs
| Drug | COX-2 selectivity | t½ | Status |
|---|---|---|---|
| Lumiracoxib | Highest | ~3-6 h | Withdrawn (hepatotoxicity) |
| Etoricoxib | Second highest | ~22 h | Available in Europe/Asia |
| Celecoxib | Moderate | ~11 h | Available worldwide (incl. US) |
| Valdecoxib | Moderate | ~8-11 h | Withdrawn (CV + skin reactions) |
| Rofecoxib | High | ~17 h | Withdrawn (CV toxicity - VIGOR trial) |
Most coxibs have been either restricted or withdrawn due to adverse cardiovascular risk profiles. Etoricoxib remains in clinical use in many countries outside the US.
Key clinical takeaway: Etoricoxib offers excellent once-daily dosing convenience, high COX-2 selectivity (less GI toxicity than non-selective NSAIDs), and proven efficacy in arthritis, gout, and axial spondyloarthritis - but shares the class cardiovascular risk of all COX-2 inhibitors and is not available in the United States.
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th ed.; Rheumatology 2-Volume Set (Elsevier, 2022)
This is a shared conversation. Sign in to Orris to start your own chat.